BPC-157 prescription: frequently asked questions.

No. BPC-157 is currently FDA Category 2, prohibiting compounding pharmacies from preparing it in any form — injectable, oral, or nasal spray. HHS has announced intent to reclassify to Category 1, but the formal rule has not been published. No legal BPC-157 prescription pathway exists in the United States as of April 2026.

The optimal route depends on your treatment goal. Subcutaneous injection is preferred for localized injuries — tendons, ligaments, joints, muscle tears — because it delivers higher concentrations near the target tissue. Oral BPC-157 capsules are preferred for gut healing applications (IBS, leaky gut, gastric ulcers, inflammatory bowel conditions) because BPC-157 acts directly on the GI lining during transit and maintains oral bioavailability due to its gastric origin. BPC-157 nasal spray is a third option with faster systemic absorption than oral and without the need for injection; it is sometimes preferred for systemic anti-inflammatory or neuroprotective applications but has the least published clinical data of the three routes.

The BPC-157 and TB-500 stack is the most common peptide combination for accelerated tissue repair. BPC-157 promotes angiogenesis, collagen organization, and growth hormone receptor upregulation. TB-500 (Thymosin Beta-4 fragment) promotes cell migration, actin polymerization, and stem cell differentiation. The two peptides work through complementary mechanisms — BPC-157 builds the repair infrastructure while TB-500 mobilizes the cells that do the building. Combined BPC-157 and TB-500 dosage is typically 250–500 mcg BPC-157 plus 750 mcg TB-500, both injected subcutaneously once daily. Many practitioners report synergistic results from the stack that exceed either peptide used alone. Monthly cost for the BPC-157 and TB-500 stack is approximately $200–$350.

The wolverine peptide is a nickname for BPC-157 used in the peptide therapy and biohacking community. The name references the Marvel character Wolverine's superhuman healing ability and reflects BPC-157's unusual breadth of tissue repair effects across muscle, tendon, ligament, bone, nerve, gut, and vascular tissue. The wolverine peptide is BPC-157 — same compound, same sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), same 15 amino acids. The healing is real but gradual over weeks, not instantaneous like the fictional character.

BPC-157 for gut health is one of the most well-supported applications in the research literature. The peptide originates from gastric juice — it literally evolved to protect and repair the GI tract. Published research demonstrates healing across gastric ulcers, NSAID-induced gut damage, inflammatory bowel conditions, esophageal lesions, and intestinal barrier dysfunction (leaky gut). Oral BPC-157 is the preferred route for gut health applications because it delivers the peptide directly to the GI lining. Two small human trials for inflammatory bowel conditions showed positive preliminary results.

Based on pre-restriction compounding pharmacy pricing, expect $120–$220 per month for injectable BPC-157 or $80–$150 for oral formulations. The BPC-157 and TB-500 stack runs $200–$350 monthly. Physician consultation fees ($100–$250 initial, $50–$100 follow-up) are additional. Insurance will not cover compounded BPC-157. HSA/FSA may be eligible with physician documentation.

If Category 1 reclassification occurs, yes. Telehealth peptide therapy providers were the primary BPC-157 prescribers before the Category 2 restriction. The process is straightforward: telehealth video consultation with a licensed physician, medical history review and treatment plan discussion, electronic prescription sent to a licensed compounding pharmacy, pharmacy ships the prepared peptide directly to your address. No in-person visit is required in most states.

BPC-157 has demonstrated a favorable safety profile across hundreds of published animal studies — no lethal dose has been identified, and the therapeutic window is remarkably wide. Clinical practice experience prior to the Category 2 restriction was consistent with a mild side effect profile (injection site reactions, occasional nausea). However, comprehensive human safety data from controlled clinical trials does not exist. The primary theoretical concern is angiogenesis in the context of active malignancy. BPC-157 is contraindicated in active cancer, pregnancy, and individuals under 18.

BPC-157 is not a controlled substance and its use is not criminalized. However, it is banned by WADA (World Anti-Doping Agency) under the S0 non-approved substance category and by the NCAA under the same framework. Competitive athletes will test positive for BPC-157 and face suspension. The FDA Category 2 classification restricts compounding but is a regulatory restriction, not a criminal prohibition. A potential Category 1 reclassification could restore prescription access but would not change WADA or NCAA status.